Although the initiation of inflammatory pain (hyperalgesia) has been demonstrated to require the cAMP second messenger signaling cascade, whether this mechanism and/or other mechanisms underlie the continued maintenance of the induced hyperalgesia is unknown. We report that injection of adenylyl cyclase inhibitors before but not after injection of direct-acting hyperalgesic agents (prostaglandin E 2 and purine and serotonin receptor agonists) resulted in reduction in hyperalgesia, evaluated by the Randall-Selitto paw-withdrawal test. In contrast, injection of protein kinase A (PKA) inhibitors either before or after these hyperalgesic agents resulted in reduced hyperalgesia, suggesting that hyperalgesia after its activation was maintained by persistent PKA activity but not by adenylyl cyclase activity. To evaluate further the role of PKA activity in the maintenance of hyperalgesia, we injected the catalytic subunit of PKA (PKACS) that resulted in hyperalgesia similar in magnitude to that induced by the direct-acting hyperalgesic agents but much longer in duration (Ͼ48 vs 2 hr). Injection of WIPTIDE (a PKA inhibitor) at 24 hr after PKACS reduced hyperalgesia, suggesting that PKACS hyperalgesia is not independently maintained by steps downstream from PKA. In summary, our results indicate that, once established, inflammatory mediatorinduced hyperalgesia is no longer maintained by adenylyl cyclase activity but rather is dependent on ongoing PKA activity. An understanding of the mechanism maintaining hyperalgesia may provide important insight into targets for the treatment of persistent pain.
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Tissue injury results in the production of inflammatory mediators, several of which sensitize primary afferent nociceptors (Martin et al., 1987; Schaible and Schmidt, 1988; Davis et al., 1993; Rueff and Dray, 1993) , resulting in hyperalgesic pain (tenderness) (Collier and Schneider, 1972; Moncada et al., 1975; Ferreira et al., 1978; Ferreira, 1981) . Inflammatory mediators such as prostaglandin E 2 (PGE 2 ), adenosine, and serotonin (5-HT) act directly on primary afferent nociceptors to decrease the activation threshold and to increase the response to a constant intensity stimulus , 1990 , 1992 England et al., 1996; Gold et al., 1996a) . A substantial literature suggests that PGE 2 -, 5-HT-, and adenosine-induced hyperalgesia, as well as hyperalgesia induced by tissue damage, is initiated by activation of the adenylyl cyclase (AC)-cAM P-protein kinase A (PK A) second messenger cascade Taiwo and Levine, 1990 , 1992 Pitchford and Levine, 1991; K hasar et al., 1995; England et al., 1996; Malmberg et al., 1997) . Voltage-gated sodium currents may be modulated by PK A. Although the majority of voltage-gated sodium currents modulated by PK A are inhibited, it has been shown that PK A is able to enhance the tetrodotoxin-resistant sodium current (England et al., 1996; C ardenas et al., 1997; Gold et al., 1999 ), a sodium current found primarily in nociceptors (Akopian et al., 1996; Sangameswaran et al., 1996) , that is thought to underlie inflammatory mediator-induced sensitization of nociceptors (England et al., 1996; Gold et al., 1996a; C ardenas et al., 1997) and hyperalgesia (Khasar et al., 1999) . Thus, agents that inhibit AC and cAMP-dependent protein kinase (PKA) prevent induction of hyperalgesia by PGE 2 , CGS21680, and 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT).
Because of the important ramifications for treatment of chronic inflammatory pain, we investigated whether ongoing activity in the cAMP second messenger pathway contributes to maintenance as well as initiation of hyperalgesia and, if so, which steps in the cAMP second messenger cascade determine duration of the hyperalgesia.
MATERIALS AND METHODS
Animals. E xperiments were performed on male Sprague Dawley rats (200 -250 gm; Bantin-K ingman, Fremont, CA). Animals were housed in groups of two under a 12:12 hr light /dark cycle. Food and water were available ad libitum. All behavioral testing was done between 10:00 A.M. and 4:00 P.M. E xperiments were performed under approval of the Institutional Animal C are Committee of the University of C alifornia, San Francisco.
Behavioral testing. The nociceptive flexion reflex was quantified with a Basile Analgesymeter (Stoelting, Chicago, IL), which applies a linearly increasing mechanical force to the dorsum of the rat's hindpaw. The mean baseline threshold was determined as the mean of three readings before the administration of the test agent. The mean baseline threshold, before treatments, for the rats used in these experiments was 109.0 Ϯ 0.45 gm (mean Ϯ SEM; n ϭ 284 paws). Mechanical threshold was redetermined at three time points (15, 20, and 25 min) after treatments. The mean of these three readings was considered to be the pawwithdrawal threshold because of drug administration, and this value was used to calculate the percentage change from the baseline threshold for each paw.
The onset of hyperalgesia was determined by assessing 1, 2, 3, 4, and 5 min after injection of a hyperalgesic agent.
Drug administration. The agents used in this study were PGE 2 (Sigma, St. L ouis, MO); WIPTIDE, 8-OH-DPAT, CGS21680, and SQ22356 (Research Biochemicals, Natick, M A); protein kinase A catalytic subunit (PK AC S) and RpcAM PS (C albiochem, La Jolla, CA); dideoxyadenosine (ddA) (courtesy of Dr. Johnson, State University of New York, Stony Brook, N Y); and SC19220 (a generous gift from G. D. Searle). The selection of the doses used was based on the dose -response curves determined in this or previous studies Levine, 1997, 1998) . The stock solution of PGE 2 (1 g /2.5 ml) was prepared in 10% ethanol, and f urther dilutions were made in saline; the final concentration of ethanol was Յ1%. PKACS and WIPTIDE were dissolved in saline. All drugs were administered intradermally in a volume of 2.5 l /paw. For test agents with low cell membrane permeability (WIPTIDE and PK AC S), coinjection of 2 l of distilled water, to produce hypo-osmotic shock and facilitate cell permeability to these agents, was used (West and Huang, 1980; Burch and Axelrod, 1987; Leidenheimer and Harris, 1991) . When combinations of agents were used, they were administered from the same syringe in such a way that the agent mentioned first reached the intradermal site first; similarly, the distilled water preceded agents with low cell membrane permeability. The agents were separated in the syringe by a small air bubble to prevent their mixing in the syringe.
To enhance our ability to analyze a specific second messenger system (that is, to ensure the greatest specificity in block of f unction), we have (1) used multiple inflammatory mediators known to be direct-acting hyperalgesic agents producing hyperalgesia by the cAM P-PK A second messenger signaling pathway, (2) used the most specific blockers available, (3) used more than one specific blocker of a single target in the second messenger pathway, and (4) used blockers at multiple sites in the same second messenger pathway.
Statistics. Data are presented as mean Ϯ SEM; statistical significance was determined by ANOVA followed by Scheffe's post hoc test, and p Ͻ 0.05 was considered statistically significant.
RESULTS
Injection of PGE 2 (100 ng) resulted in a significant decrease in the nociceptive threshold that reached peak magnitude by 5 min (Fig.  1 A) . Injection of an adenylyl cyclase inhibitor, ddA or SQ22356, before PGE 2 reduced PGE 2 -induced hyperalgesia; however, if injected 5 min after PGE 2 , ddA or SQ22356 had no effect on the established PGE 2 hyperalgesia (Fig. 1C) . Similarly, injection of the E-type prostaglandin receptor antagonist SC19220 before but not 5 min after PGE 2 attenuated PGE 2 -induced hyperalgesia (Fig. 1C) . Injection of a PKA inhibitor, WIPTIDE or RpcAMPS, before PGE 2 also inhibited PGE 2 -induced hyperalgesia ( Fig. 1 D) ; however, unlike the cyclase inhibitors, WIPTIDE or RpcAMPS injected 5 min after PGE 2 was also able to inhibit PGE 2 hyperalgesia. These results suggest that, 5 min after its induction, PGE 2 hyperalgesia is maintained by PKA activity and that adenylyl cyclase activity is no longer required.
To evaluate the generalizability of this role of PKA in the maintenance of inflammatory hyperalgesia, we determined the effect of adenylyl cyclase and PKA inhibitors on hyperalgesia Figure 1 . A, Latency of onset of PGE 2 -induced mechanical hyperalgesia in the hindpaw of the rat (n ϭ 12). B, Time course of PGE 2 -induced mechanical hyperalgesia (n ϭ 12). C, Effect on PGE 2 -induced mechanical hyperalgesia (n ϭ 22; p Ͻ 0.05) of the adenylyl cyclase inhibitors ddA and SQ22356 (SQ) when administered before [ddA/PGE 2 , n ϭ 8; *p Ͻ 0.05; SQ/PGE 2 , n ϭ 6; *p Ͻ 0.05; SC19220 (SC)/PGE 2 , n ϭ 6; *p Ͻ 0.05] or 5 min after (PGE 2 /ddA, n ϭ 10; p Ͼ 0.05; PGE 2 /SQ, n ϭ 8; p Ͼ 0.05) intradermal administration of PGE 2 . D, Effect of PK A inhibitors [W IPTIDE and R pcA MPS (RpcAMP)] when administered before (W IPTIDE/PGE 2 , n ϭ 10; *p Ͻ 0.05; R pcA MP/PGE 2 , n ϭ 6; *p Ͻ 0.05) or 5 min after (PGE 2 /W IPTIDE, n ϭ 10; *p Ͻ 0.05; PGE 2 /RpcAMP, n ϭ 6; *p Ͻ 0.05) intradermal administration of PGE 2 . NS, Not significant. induced by two other direct-acting hyperalgesic agents, 8-OH-DPAT (5-HT 1A serotonin receptor agonist) and CGS21680 (A 2 adenosine receptor agonist) Levine, 1990, 1992) . Injection of 8-OH-DPAT and CGS21680 resulted in a significant decrease in nociceptive threshold (Figs. 2, 3, respectively) . Hyperalgesia induced by 8-OH-DPAT or CGS21680 was f ully established by 5 min. Injection of the adenylyl cyclase inhibitors ddA and SQ22356 immediately before 8-OH-DPAT and CGS21680 resulted in reduced hyperalgesia; however, if injected 5 min after 8-OH-DPAT and CGS21680, ddA and SQ22356 had no effect on established hyperalgesia. Injection of a PK A inhibitor, WIP-TIDE or RpcAM PS, before 8-OH-DPAT or CGS21680 also inhibited induction of hyperalgesia (Figs. 2, 3) ; injected 5 min after 8-OH-DPAT or CGS21680, WIPTIDE or RpcAMPS was still able to inhibit hyperalgesia.
To determine whether "exogenous," persisting PK A activity mimics inflammatory mediator-induced hyperalgesia, we injected the PK AC S that can be introduced to an intracellular location by a preceding injection of distilled water to produce hypoosmotic shock (Burch and Axelrod, 1987; K hasar et al., 1995) . Injection of PK AC S produced hyperalgesia similar in magnitude to that produced by PGE 2 but lasting at least 48 hr (Fig. 4) . Injection of WIPTIDE before PKACS inhibited PK AC S hyperalgesia (Fig. 4) . WIPTIDE was also able to reverse PKACS hyperalgesia when injected 5 min, 6 hr, or 24 hr after PKACS.
DISCUSSION
All steps of the cAMP second messenger cascade have been shown to be necessary for the induction of hyperalgesia by directacting agents. However, our results indicate that at 5 min after injection, hyperalgesia is maintained by PKA and is independent of upstream activity in the cAMP-PKA second messenger cascade. The fact that WIPTIDE can inhibit PKACS-induced hyperalgesia when administered at any point during its time course suggests that the hyperalgesia is not maintained by persistence of the changes in the cell downstream from PKA, such as longlasting enhancement of ion channels, such as the tetrodotoxinresistant sodium current, the probable downstream target for PKA in nociceptors mediating sensitization (England et al., 1996; Gold et al., 1996a; Cardenas et al., 1997) and hyperalgesia (Khasar et al., 1999) .
Furthermore, because administration of PKACS (essentially an excess of PKA, devoid of its regulatory subunit) produces prolonged hyperalgesia, with a time course consistent with that of metabolic degradation of PKACS (Lee and Steinberg, 1996) , the observed time course of hyperalgesia after PGE 2 seems to reflect the time course of PKA activation. That PKACS hyperalgesia could be reversed by PK A inhibitors even 24 hr after onset of hyperalgesia f urther suggests that mechanisms downstream from PKA activity are not effective in the maintenance of the observed hyperalgesia.
If cAM P levels remain persistently elevated, cells undergo changes in their A kinase signaling system; some cells alter the rate of degradation of PK A subunits, and some change the stability of the messages encoding subunits (Spaulding, 1993; Dunbar and Kalinski, 1994; Garrel et al., 1995; Spatz, 1995; Knutsen et al., 1997) . Therefore, prolonged hyperalgesia after a sustained exposure to hyperalgesic inflammatory mediators may result from prolonged exposure to cAM P and consequent independently persisting activity of the PK A catalytic subunit because of changes in the ratio of catalytic to regulatory subunits. For example, in nociceptor-like neurons in Apl ysia (C latworthy and Walters, 1993a,b; Dulin et al., 1995; O'Leary et al., 1995) , PKA plays an important role in the facilitation that mediates both short-and long-term sensitization (Kandel and Schwartz, 1982; Bailey and Kandel, 1993; Byrne et al., 1993) . After exposure to the facilitating neurotransmitter serotonin, protein kinase A activity becomes persistently elevated at basal cAM P levels, because of a decrease in the ratio of the concentration of regulatory to catalytic subunits (Sweatt and Kandel, 1989; Chain et al., 1995) . Our demonstration that administration of PK ACS produces prolonged hyperalgesia, compatible with its rate of metabolism, suggests that a modification of its metabolism could contribute to chronic hyperalgesic states.
In summary, we have provided evidence for the first time that maintenance of hyperalgesia involves a mechanism distinct from the initiating mechanism. Understanding of the mechanisms maintaining hyperalgesia can provide rationales for novel targets for the treatment of chronic inflammatory pain. Specifically, the results of the present study suggest that continued exposure to inflammatory mediators may not be needed to maintain chronic hyperalgesic pain and, therefore, that the most effective site for therapeutic intervention may not be the cell surface receptor in primary afferent nociceptors but the responsible intracellular second messengers. This observation might also underlie the development of resistance to agents that block the production of hyperalgesic inflammatory mediators, such as the nonsteroidal anti-inflammatory drugs, inhibitors of the synthesis of prostaglandins.
